New advances in the use of cell-free fetal DNA (cffDNA) in maternal plasma of pregnant women has provided the possibility of applying cffDNA in prenatal diagnosis as a non-invasive method. One of the applications of prenatal diagnosis is fetal gender determination. Early prenatal determination of fetal sex is required for pregnant women at risk of X-linked and some endocrine diseases. The present study was carried out to perform an efficient polymerase chain reaction (PCR) method in order to improve sensitivity, specificity and accuracy of non-invasive fetal gender detection using fetal DNA in maternal plasma during 8th -12th weeks of pregnancy. Materials and Methods: Thirty-five pregnant women with 8 to 12 weeks of pregnancy were selected for prenatal fetal sex determination. Maternal peripheral blood was collected and cffDNA was extracted from 3-ml of maternal plasma. Two multi copy Y-chromosome-specific region (DYS and DAZ) and a single copy gene (SRY) were amplified by real-time quantitative PCR. Amplification was labeled as positive, negative, or inconclusive according to a stringent algorithm. Results: Using this method, the sensitivity and specificity of the real-time PCR assay was 100% and 93.8% for prenatal fetal sex detection, respectively. Conclusions: It is concluded that fetal sex can be determined with a high level of accuracy by our algorithm, after 8 weeks of gestation with cffDNA analysis.
Introduction
The presence of cell-free fetal DNA (cffDNA) in maternal plasma and serum was first recognized in 1997 [1] , and its clinical applications continue to expand thereafter. Noninvasive prenatal diagnosis requires maternal serum analysis detecting the cell-free fetal DNA which avoids the risk of miscarriage associated with invasive procedures such as aminocentesis or chorionic villous sampling [2] . The origin of the cffDNA has remained uncertain although different hypotheses are supposed to derive from dead cells due to necrosis or apoptosis [3] , or an active cells release [4] from the placenta or, more specifically, trophoblast as the most likely source [5] . The concentration of cffDNA is low in the first trimester but it rises in the second and third trimester of pregnancy [1] .
The cffDNA has been shown to exist in plasma and serum of pregnant women as early as 6 weeks of gestation with concentrations rising during pregnancy and peaking prior to parturition and clears within several hours after birth [6] . The analysis of cffDNA in maternal serum and plasma is currently the method of choice for the noninvasive determination of fetal genetic traits [7] .
Early prenatal determination of fetal sex is required for identifying pregnant women at risk of fetal aneuploidy and X-linked diseases.
The identification of a male fetus indicates hemizygosity for the X chromosome and could indicate potential diseases if the mother is a carrier [8] .
Several reports have been published by targeting Y-chromosome-specific genes in maternal plasma for fetal sex determination.
Both the single-copy SRY gene sequence [9] and multi-copy regions of the Y chromosome such as DYS14 marker sequence of the TSPY gene [10] and DAZ family [11] have been analyzed with polymerase chain reaction (PCR). Real-time quantitative PCR (RT-PCR), providing data in a real-time manner, is amenable to automation and less prone to contamination in comparison with conventional PCR methods [12] . Although results are encouraging, the diagnostic accuracy varies widely depending on the protocols and methods used with sensitivity and specificity ranging from 31% to 100% [13] . The present study was carried out to perform new PCR method so as to improve sensitivity specificity and accuracy of non-invasive detection of cffDNA in maternal plasma during 8 th -12 th weeks of pregnancy. The hypothesis was that early fetal gender determination using these tests are highly accurate when performed after 6 weeks using stringent reporting criteria that includes a third Y-chromosome-specific sequence for confirmation.
Materials and Methods

Study specimens
The study was performed during one year. Supernatants were stored at -80˚C until DNA extraction.
DNA extraction from plasma
cffDNA was extracted from 3 ml of maternal plasma using the DNP® kit (Sinaclon, Karaj, Iran) according to the manufacture's protocol with some modifications. Reagents were increased proportionately to accommodate the 3 ml sample size. DNA was eluted in 100 μL of elution buffer (provided in the kit) and kept at -80˚C until PCR analysis.
Real-time PCR
The RT-PCR assays were performed using the Rotor-Gene Q 6000 RT-PCR machine )RotorGene Q 6000 System, Qiagene, USA). The Ychromosome-specific region-a multi-copy marker (DYS14)-was systematically analyzed in all cases to increase the sensitivity and specificity of the assay. An additional multicopy sequence (DAZ) and a single copy gene 
Statistical analysis
After collection of all pregnancy outcomes, descriptive statistics were performed using Prism 5 software (GraphPad Software, San Diego, CA). The Fisher exact test (two-sided) was used to determine the test sensitivity and specificity with 95% confidence intervals. The positive predictive value and negative predictive value were also evaluated. To date, several special kits for isolation of cffDNA from maternal plasma have been introduced [16] . All these kits are highly expensive so that the cost effectiveness of the process of cffDNA extraction needs to be considered. Here we used a new method for cffDNA extraction and showed that it was completely efficient. False-positive results are mainly the consequence of contamination during sample preparation or PCR procedure.
RT-PCR reduces the risk of contamination because it has a closed system. Another reason for false-positive results is multi-copy sequences. It has been observed that a multicopy sequence, such as DYS14, is more sensitive, accurate, and efficient than the singlecopy SRY in the assessment of cffDNA, which is particularly important early in the first trimester of pregnancy when the copy numbers of fetal DNA are low [17] . When DYS14 is used alone for prenatal fetal sex determination, a high frequency of amplification signals are obtained in female fetuses (35% vs. 63.9%) [18] . The drawback of the DYS14 sequence, however, is that it has considerable homology to sequences other than the Y chromosome.
This probably is the reason of false positive results by amplification of this gene [10] . because of undetectable levels of cffDNA.
Some studies have used a combination of the DYS14 and SRY sequences to improve sensitivity and specificity of the assay [22] [23] or testing for only DYS14 has been suggested in some other studies because of the higher sensitivity for this sequence [10] [11] [12] [13] [14] [15] [16] [17] . Analysis based on only DYS14 requires to set a cut off for threshold cycle (Ct) in qPCR analysis that may be inconsistant in the laboratories.
In this study, a case analyzed simultaneously with DYS14, DAZ and SRY and a robust algorithm for reporting fetal sex was designed to overcome the false-positive and false-negative results. The inclusion of two multicopy Ychromosome-specific assays increased the sensitivity and matching the results with SRY increased the specificity as a whole.
Conclusion
Noninvasive fetal sex determination in maternal plasma can be translated into clinical practice for gender specific inherited disorders. We conclude that fetal sex can be determined with a high level of accuracy by analyzing cffDNA after 8 weeks of gestation using different Y specific loci and it is hoped that applying this method for non-invasive prenatal diagnosis can also be extended for single gene disorders. The need for invasive diagnostic testing in women with a high risk of sex-linked genetic disease can be significantly reduced through this test.
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